Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31742565 | 0.91 | CHRNB2 (0.65) | CHRNB2CHRNA4CYP3A4LMNA | |
| SCHEMBL30338591 | 0.89 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL171896 | 0.89 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP2C9CYP2C19CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL7207615 | 0.87 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL422229 | 0.84 | CYP2C9 (0.70) | CHRNB2CHRNA4CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL29469519 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP3A4KMT2A | |
| SCHEMBL12568183 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP3A4KMT2A | |
| SCHEMBL20930335 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL20730105 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL9367178 | 0.81 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806409-B2 | Imaging methods using 18F-radiolabeled biologics | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210196843-A1 | IMAGING METHODS USING 18F-RADIOLABELED BIOLOGICS | BRISTOL-MYERS SQUIBB COMPANY | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196843-A1 | IMAGING METHODS USING 18F-RADIOLABELED BIOLOGICS | FCGRT, FAP, FUCA1 | CHRNB2 4370/4885CHRNA4 4850/4885CYP2C9 2669/4885 |
| US-11806409-B2 | Imaging methods using 18F-radiolabeled biologics | FCGRT, FAP, FUCA1 | CHRNB2 4370/4885CHRNA4 4850/4885CYP2C9 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.